CYTH
NASDAQCyclo Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Latest news
25 items- SECSEC Form 15-12G filed by Cyclo Therapeutics Inc.15-12G - Cyclo Therapeutics, Inc. (0000922247) (Filer)
- SECCyclo Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)
- PRRafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder ApprovalsNEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics' shareholders representing approximately 22% of the combined company, based on the exchange ratio in the merger agreement between the parties determined to be 0.3525. Rafael also issued warrants to purchase shares of Rafael Class B common stock to certain holders of Cyclo warrants. Rafael Holdings has identified Trappsol® Cyclo™ as its lead clinical asset
- SECCyclo Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)
- PRRafael Holdings Reports Second Quarter Fiscal 2025 Financial ResultsThe planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo's lead clinical program Trappsol® Cyclo™ NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025. "We look forward to the upcoming shareholder vote on our pending merger with Cyclo Therapeutics (NASDAQ:CYTH) later this month and anticipate closing promptly post shareholder approvals. Upon closing, the Company's strategic focus will be on its lead clinical asset, T
- SECCyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)
- INSIDERDirector Conkling William was granted 27,654 shares, increasing direct ownership by 55% to 77,884 units (SEC Form 4)4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)
- INSIDERDirector Wong Vivien was granted 25,140 shares, increasing direct ownership by 63% to 64,853 units (SEC Form 4)4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)
- INSIDERDirector Cross Shawn was granted 28,597 shares, increasing direct ownership by 27% to 136,346 units (SEC Form 4)4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)
- INSIDERDirector Toig Randall M. was granted 33,311 shares, increasing direct ownership by 23% to 179,137 units (SEC Form 4)4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)
- INSIDERDirector Strattan Ce Rick was granted 30,169 shares, increasing direct ownership by 8% to 399,272 units (SEC Form 4)4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)
- INSIDERDirector Ostronic Francis Patrick was granted 70,329 shares, increasing direct ownership by 20% to 419,100 units (SEC Form 4)4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)
- INSIDERDirector Sieger Markus was granted 58,138 shares, increasing direct ownership by 15% to 440,260 units (SEC Form 4)4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)
- INSIDERDirector Shanahan William S was granted 25,140 shares, increasing direct ownership by 17% to 173,966 units (SEC Form 4)4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)
- PRCyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)First data in NPC1 on treatment in this age group over a period of 48 weeks At 24 weeks of the sub-study, 7 of 8 patients (87%) and at 48 weeks of the sub-study, 6 of 7 patients (86%) show stabilization or improvement in Clinical Global Impression – Change (CGI-C) Scale Data presented at the 21st Annual WORLDSymposium™ 2025 Company on track for topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ in H1 2025 Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with rare and
- SECCyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)
- PRCyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") to be highlighted in an oral presentation Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstracts have been accepted for oral and poster presentation at the 21st Annual WORLDSymposium™ being held February 3-7, 2025 in San Diego, CA. Details of the presentations are as follows: Oral Presentation: Title: Trappsol® Cyclo™: Open Label Treatment in the Transp
- SECCyclo Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)
- SECCyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)
- SECCyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Cyclo Therapeutics Inc.10-K/A - Cyclo Therapeutics, Inc. (0000922247) (Filer)
- PRRafael Holdings Reports First Quarter Fiscal 2025 Financial ResultsNEWARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the first quarter of fiscal year 2025 ended October 31, 2024. "We anticipate proceeding to a shareholder vote on our pending merger agreement with Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the first calendar quarter of 2025 and closing promptly post shareholder approvals. Upon closing of the merger, the Company intends to focus its strategic efforts and resources on what will then be the Company's lead clinical program and core asset, Trappsol® Cyclo™. Accordingly, we are currently evaluating our other operating entities and portfolio of assets," said Bill Conkling, C
- SECCyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Cyclo Therapeutics Inc.10-K/A - Cyclo Therapeutics, Inc. (0000922247) (Filer)
- INSIDERDirector Conkling William was granted 16,660 shares, increasing direct ownership by 50% to 50,230 units (SEC Form 4)4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)
CYTH FAQ
5 questionsWhat does Cyclo Therapeutics Inc. do?
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based...Where does CYTH stock trade?
Cyclo Therapeutics Inc. (CYTH) is listed on NASDAQ.What sector and industry is CYTH in?
Cyclo Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to CYTH?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CYTH side-by-side with any of them on Quantisnow.How can I track CYTH on Quantisnow?
Quantisnow aggregates Cyclo Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CYTH to receive live email and push alerts on every new disclosure.